P-349. Using Participatory Design to Establish a Workflow for Administration of Long-Acting Cabotegravir + Rilpivirine in Community Pharmacies

Abstract Background Long acting cabotegravir and rilpivirine (LA CAB/RPV), the first fully injectable antiretroviral therapy for people with HIV (PWH), is administered intramuscularly typically by a nurse in a clinic. Limitations to this approach include staff availability, office hour restrictions, travel distance, and HIV stigma. Alternate models of care are needed to address these obstacles expanding access to LA CAB/RPV. We used a human-centered participatory approach to co-design a workflow adapting in clinic administration of LA CAB/RPV to community pharmacies. Workflow for Long-acting Cabotegravir/Rilpivirine Administration in Community Pharmacies Methods Our design team consisted of 12 members, including HIV providers, pharmacists, nurses, informaticists, and PWH receiving LA CAB/RPV. The team met weekly for 5 sessions to delineate current practices and iteratively produce a modified workflow. We assessed barriers and facilitators of co-design through semi-structured interviews with design team members. A phenomenologically informed codebook thematic analysis identified key themes across interviews. Results Factors identified as essential to the in clinic model of LA CAB/RPV administration included care coordination utilizing electronic health record reports to track patient follow-up, communication among the team and with the patient, and injection visit experience. The figure shows the workflow adapted to community pharmacies. Next, from interviews with 6 design team members, we identified 4 themes of successful co-design. First, meeting modality created essential infrastructure for collaboration with in-person interactions enabling more effective engagement. Second, strategic leadership shaped the process with atomization of a complex workflow into manageable steps which involved work between meetings to frame and organize discoveries. Third, team composition and inclusivity enriched the process where multidisciplinary representation contributed critical insights. Last, collaborative humility fostered participation across power differentials aiding the integration of expertise from all participants. Conclusion Using co-design, we were able to adapt the workflow for in clinic administration of LA CAB/RPV to community pharmacies. Structural, compositional and interpersonal team factors contributed to the successful co-design process. Disclosures Melissa O. Jenkins, Meliisa Jenkins, Gilead Sciences, Inc.: Grant/Research Support Corrilynn O. Hileman, MD, MS, Gilead: Grant/Research Support|ViiV: Grant/Research Support

Authors

Institutions

Publication Details

Journal
Open Forum Infectious Diseases
Published
2026-01-01
DOI
https://doi.org/10.1093/ofid/ofaf695.567
Primary Topic
HIV, Drug Use, Sexual Risk
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

P-349. Using Participatory Design to Establish a Workflow for Administration of Long-Acting Cabotegravir + Rilpivirine in Community Pharmacies

Nicholas M. Riley, Melissa O. Jenkins, Ann A Avery, Corrilynn O. Hileman et al.
Open Forum Infectious Diseases
HIV, Drug Use, Sexual Risk
article

P-349. Using Participatory Design to Establish a Workflow for Administration of Long-Acting Cabotegravir + Rilpivirine in Community Pharmacies

Nicholas M. Riley, Melissa O. Jenkins, Ann A Avery, Corrilynn O. Hileman, Kristen Andrea Berg, Alexander Nelson, Margaret Oblak, Joshua Maierhofer, Morgan K Morelli, Ashley M Hughes, Demetria Webb, Luke Forkapa
article en

Abstract

Abstract Background Long acting cabotegravir and rilpivirine (LA CAB/RPV), the first fully injectable antiretroviral therapy for people with HIV (PWH), is administered intramuscularly typically by a nurse in a clinic. Limitations to this approach include staff availability, office hour restrictions, travel distance, and HIV stigma. Alternate models of care are needed to address these obstacles expanding access to LA CAB/RPV. We used a human-centered participatory approach to co-design a workflow adapting in clinic administration of LA CAB/RPV to community pharmacies. Workflow for Long-acting Cabotegravir/Rilpivirine Administration in Community Pharmacies Methods Our design team consisted of 12 members, including HIV providers, pharmacists, nurses, informaticists, and PWH receiving LA CAB/RPV. The team met weekly for 5 sessions to delineate current practices and iteratively produce a modified workflow. We assessed barriers and facilitators of co-design through semi-structured interviews with design team members. A phenomenologically informed codebook thematic analysis identified key themes across interviews. Results Factors identified as essential to the in clinic model of LA CAB/RPV administration included care coordination utilizing electronic health record reports to track patient follow-up, communication among the team and with the patient, and injection visit experience. The figure shows the workflow adapted to community pharmacies. Next, from interviews with 6 design team members, we identified 4 themes of successful co-design. First, meeting modality created essential infrastructure for collaboration with in-person interactions enabling more effective engagement. Second, strategic leadership shaped the process with atomization of a complex workflow into manageable steps which involved work between meetings to frame and organize discoveries. Third, team composition and inclusivity enriched the process where multidisciplinary representation contributed critical insights. Last, collaborative humility fostered participation across power differentials aiding the integration of expertise from all participants. Conclusion Using co-design, we were able to adapt the workflow for in clinic administration of LA CAB/RPV to community pharmacies. Structural, compositional and interpersonal team factors contributed to the successful co-design process. Disclosures Melissa O. Jenkins, Meliisa Jenkins, Gilead Sciences, Inc.: Grant/Research Support Corrilynn O. Hileman, MD, MS, Gilead: Grant/Research Support|ViiV: Grant/Research Support

Open Forum Infectious DiseasesVol. 13(Supplement_1)
MetroHealth (US), University School (US), MetroHealth Medical Center (US), Case Western Reserve University (US)
Industry, innovation and infrastructure
Openalex Percentile: Top 92%
HIV, Drug Use, Sexual Risk
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.